A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses
Kathleen Medora / aacr - A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses PHILADELPHIA – A vaccine targeting common KRAS mutations was safe and stimulated KRAS-specific T-cell responses in 90% of study participants who…
AI Summary: An experimental KRAS-targeting vaccine administered to people at high risk for pancreatic cancer proved safe and generated durable immune responses, suggesting a credible path toward interception of pancreatic ductal adenocarcinoma before it takes hold. Researchers report sustained antibody and/or T-cell activity, supporting further development and larger efficacy trials.
#pharmaceuticals #biotech #drugdevelopment #vaccinesafety #oncology #pancreaticcancer #cancerresearch #clinicaltrials
- Broader KRAS-targeting research and technological advances (3)
- Expert and community reactions to KRAS vaccine results (3)
- Phase I KRAS vaccine: safety and durable immune responses (3)